Showing results (211-220 of 248) with videos related to
Sort By:
Pageof 25
Annals of Internal Medicine|March 7, 2007
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialSusan L Greenspan, Henry G Bone, Mark P Ettinger, et al.Annals of Neurology|July 18, 2001
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisW I McDonald, A Compston, G Edan, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 10, 2017
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM ExtensionNelson B Watts, Jacques P Brown, Socrates Papapoulos, et al.Science (New York, N.Y.)|March 9, 2002
Antarctic krill under sea ice: elevated abundance in a narrow band just south of ice edgeAndrew S Brierley, Paul G Fernandes, Mark A Brandon, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 26, 2000
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of boneP Bianco, M Riminucci, A Majolagbe, et al.BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupR P Tonino, P J Meunier, R Emkey, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 29, 2014
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateJ P Brown, C Roux, P R Ho, et al.The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentersH G Bone, R W Downs, J R Tucci, et al.The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.Pageof 25